Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of PCV21 in Healthy Infants and Toddlers
NCT06736041Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Dec 2024
- Primary completion
- May 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 6
01
Overview
A Phase 3 trial of PCV21 in pneumococcal infection, sponsored by Sanofi. Started Dec 2024; status: active, not recruiting.
02
Drugs
PCV21
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT06736041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06736041.